Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
暂无分享,去创建一个
Debyani Chakravarty | Tom Mikkelsen | Eric C. Holland | Jason T. Huse | Tatsuya Ozawa | Nicholas J. Szerlip | Cameron W. Brennan | T. Mikkelsen | C. Brennan | J. Huse | S. Jhanwar | M. Leversha | E. Holland | D. Chakravarty | N. Szerlip | T. Ozawa | Margaret A. Leversha | Suresh Jhanwar | Alicia Pedraza | Mohammad Azim | Jeremy McGuire | Yuqiang Fang | Yuqiang Fang | J. McGuire | M. Azim | Alicia M. Pedraza
[1] P. C. de Witt Hamer. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. , 2010, Neuro-oncology.
[2] Camille Stephan-Otto Attolini,et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer , 2010, Proceedings of the National Academy of Sciences.
[3] C. Marosi,et al. Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy , 2005, Journal of Neuro-Oncology.
[4] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[5] C. Brennan,et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.
[6] X. Breakefield,et al. Brain Tumor Microvesicles: Insights into Intercellular Communication in the Nervous System , 2011, Cellular and Molecular Neurobiology.
[7] G. Thiel,et al. Karyotypes in 90 human gliomas. , 1992, Cancer genetics and cytogenetics.
[8] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[10] Eric C. Holland,et al. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.
[11] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[12] P. Humphrey,et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. , 1990, Cancer research.
[13] C. Brennan,et al. Recruited Cells Can Become Transformed and Overtake PDGF-Induced Murine Gliomas In Vivo during Tumor Progression , 2011, PloS one.
[14] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[15] J. Fawcett,et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours , 2009, Journal of Neuroscience Methods.
[16] J. Uhm,et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. , 2006, International journal of radiation oncology, biology, physics.
[17] Webster K. Cavenee,et al. Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.
[18] Catherine L Nutt,et al. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. , 2003, Cancer research.
[19] S. Pomeroy,et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. , 2011, Nature communications.
[20] A. von Deimling,et al. Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma , 2011, International journal of cancer.
[21] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[22] P. Liberski,et al. Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies , 2010, Journal of Neuro-Oncology.
[23] A. Ashworth,et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas , 2009, British Journal of Cancer.
[24] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[25] J. Troge,et al. Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.
[26] K. Aldape,et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.
[27] I. Christensen,et al. Prospective evaluation of angiogenic, hypoxic and EGFR‐related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[28] M. Nagane,et al. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. , 2011, The Journal of clinical investigation.
[29] M. Stratton,et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.
[30] C. Brennan,et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. , 2010, Genes & development.
[31] C. James,et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.
[32] M. Delorenzi,et al. Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial , 2011, Molecular Cancer Therapeutics.
[33] W. Kamphorst,et al. Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma? , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Susan M. Chang,et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.
[35] Tarik Tihan,et al. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.
[36] Denis Lacombe,et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[38] B. Vogelstein,et al. Cytogenetics and Molecular Genetics of Malignant Gliomas and Medulloblastoma , 1990, Brain pathology.
[39] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[40] Bernardo Celda,et al. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile , 2010, Modern Pathology.
[41] M Kimmel,et al. Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. , 1990, Genetics.